NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

The purchase order supports preclinical animal research, with the large-animal program expected to begin early next year.

Rhea-AI Summary

NeuroOne Medical Technologies (NMTC) secured its first pharmaceutical industry purchase order for the StereoCED drug delivery platform to support preclinical research. The order supports an animal research program for an unnamed Tier 1 global pharmaceutical company, with large-animal research expected to begin early next year.

NeuroOne completed StereoCED development in fiscal Q4. The platform combines targeted drug delivery inside the skull with recording of brain electrical activity and is available for animal research and approved investigational clinical studies. It has not received regulatory clearance or approval for commercial use. NeuroOne aims to build long-term pharmaceutical partnerships through early participation in drug development.

Positive

• Minor pointFirst pharmaceutical industry purchase order secured for StereoCED, supporting a Tier 1 global pharmaceutical company's preclinical program.
• Minor pointStereoCED development completed in fiscal Q4, meeting the company's stated timeline.
• Minor point. Forward-looking: it has not happened yet and may not happen.Large-animal research is expected to begin early next year.
• Minor pointStereoCED is available for animal research and approved investigational clinical studies.
• Minor point. Forward-looking: it has not happened yet and may not happen.Early pharmaceutical engagement is NeuroOne's stated route toward potential long-term partnerships and recurring revenue.

Negative

• None.

Key Terms

intracranial drug delivery, electrophysiological recording, eeg

3 terms

intracranial drug delivery medical

"to support a preclinical animal research program"

Delivery of a drug directly into the brain or its surrounding spaces using injections, implanted catheters or pumps, or specialized infusion techniques so the medicine bypasses the blood–brain barrier. It is used to achieve higher local drug concentrations and more targeted effects than systemic dosing but requires surgical or device procedures and carries risks such as infection, bleeding, device malfunction and limited tissue distribution.

electrophysiological recording technical

"targeted intracranial drug delivery and electrophysiological recording capabilities"

A technique that measures the electrical activity of cells, tissues, or organs by placing electrodes on or in the body and recording voltage or current changes over time. Methods range from noninvasive surface recordings (e.g., scalp or skin electrodes) to invasive probes placed inside tissue; different approaches trade off spatial detail and invasiveness, and the recordings reflect electrical signals only (not direct chemical or metabolic activity).

eeg medical

"enabling longitudinal neurological EEG monitoring before and after drug administration"

An EEG (electroencephalogram) is a medical test that records the brain’s electrical activity through small sensors placed on the scalp, similar to reading patterns of a city’s traffic to understand flow and disruptions. For investors, EEGs matter because they are central to diagnosing and monitoring neurological conditions, validating new brain-related treatments or devices, and supporting regulatory approvals and reimbursement — factors that drive market demand and revenue potential. Changes in EEG technology, usage or guidelines can affect companies that make the equipment, offer related services, or develop therapies tied to brain signals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies

EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company.

The research program is expected to commence in large animals early next year. The study will leverage StereoCED's unique combination of targeted intracranial drug delivery and electrophysiological recording capabilities, which the Company believes is the only integrated platform of its kind. Unlike other leading drug delivery devices that are not intended for implantation, StereoCED™ is designed to support extended implantation of the electrode for less than 30 days, enabling longitudinal neurological EEG monitoring before and after drug administration. This capability could provide valuable insights into the therapeutic agent’s biological activity and efficacy over time.

This first pharmaceutical industry purchase order represents a significant commercial milestone for NeuroOne and an important step in its strategy to establish StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry. By engaging with pharmaceutical partners early in therapeutic development, NeuroOne aims to establish its technology as an integral part of the drug development process. As programs advance from preclinical research through human clinical trials and potentially commercialization, continuity with an established delivery platform may reduce development complexity and create opportunities for long-term partnerships and recurring revenue.

"We said we would complete development of StereoCED™ in fiscal Q4, and we delivered," said David Wambeke, Chief Business Officer of NeuroOne. "With our first purchase order supporting a tier 1 global pharmaceutical company and StereoCED current availability for human investigational clinical studies, we are entering an exciting new phase. We believe StereoCED offers capabilities that competing drug delivery platforms do not, which positions NeuroOne to play an important role in the development of next-generation brain therapies."

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo^® Cortical Electrodes, Evo^® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System.

NeuroOne has also developed the StereoCED™ platform for targeted intracranial drug delivery, which is currently available for animal research and approved investigational clinical studies. StereoCED™ has not been cleared or approved by the FDA or any other regulatory agency. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for long-term collaborations with global pharmaceutical companies, the establishment of StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry.. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

Disclaimer: NeuroOne’s StereoCED™ Drug Delivery System is not approved/cleared for commercial use by any Regulatory agency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is NeuroOne's first pharmaceutical purchase order for StereoCED supporting?

The StereoCED purchase order supports a preclinical animal research program for a Tier 1 global pharmaceutical company. The research is expected to commence in large animals early next year.

Is NeuroOne's StereoCED approved for commercial use?

StereoCED is not cleared or approved for commercial use by any regulatory agency. It is currently available for animal research and approved investigational clinical studies.